●
(2) BERKELEY, Calif. and VANCOUVER, British Columbia, June 2, 2021-
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ( BriaCell or the Company ), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today provides an update on the overall survival (OS) data on its previously disclosed advanced breast cancer patients. These women were treated with BriaCell s lead candidate Bria-IMT™ as monotherapy and also in combination with checkpoint inhibitors, including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and Incyte s retifanlimab (manufactured and provided under a corporate collaboration with Incyte Corporation).
HLA-Typing: Cells with HLA (human leukocyte antigen) molecules on their surface determine and trigger the body s immune response. BriaCell s immunotherapy treatment appears most effective when the patient s HLA-type matches with Bria-IMT™, allowing BriaCell to pot
Mid-Afternoon Market Update: Constellation Pharmaceuticals Surges Following Acquisition News; Protalix BioTherapeutics Shares Slide benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
12.0 months average overall survival benefit, including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade III tumors Top Responder: 21.4 months survival plus 100% resolution of ‘eye-bulging’ orbital tumor Compares to 7.2-9.8 months survival in historical comparison treatment trials BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted .
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 . A total of 1,685,180 common shares of the Company were voted, representing 22.36% of the Company’s …
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce the results of its annual general and special meeting of shareholders of the Company (the ” Shareholders “) for the years ended July 31, 2019 and July 31, 2020 held on May 18, 2021 (the ” Meeting “). A total of 1,685,180 common shares of the Company (the ” Common Sh